摘要
目的观察胰高血糖素样肽1(GLP-1)受体激动剂艾塞那肽治疗肥胖2型糖尿病病人的效果及安全性。方法选取使用口服降糖药联合胰岛素控制血糖不达标的肥胖2型糖尿病病人15例,将原治疗方案中的胰岛素改为艾塞那肽,疗程12周,期间根据血糖水平微量调整口服药物用量。治疗前后测量身高、体质量并计算体质量指数(BMI),检测空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1C)、空腹C肽、餐后2hC肽、胰高血糖素(GC)、生长抑素(SS)及三酰甘油(TG)、总胆固醇(TC)水平。结果艾塞那肽治疗12周后,与治疗前比较BMI、2hPG、HbA1C、TG、TC、GC均明显降低(t=2.54～6.61,P<0.05),SS、餐后2hC肽明显升高(t=7.44、2.62,P<0.05),FPG呈下降趋势,空腹C肽呈上升趋势,但差异无显著性(P>0.05)。结论对于血糖控制不佳的肥胖2型糖尿病病人,艾塞那肽可有效降低糖血、控制体质量、改善脂代谢、降低低糖血症的风险。
Objective To observe the clinical effects and safety of GLP-1 agonist-exenatide-on obesity type 2 diabetes. Methods Fifteen patients with obesity type 2 diabetes treated with combined oral hypoglycemic agents with insulin but failed to control their blood sugar were selected. Exenatide was used to replace insulin that used in the initial protocol, lasting for 12 weeks. During the treatment, micro-adjustment of the dose of oral medicine was done according to the levels of blood sugar. Before and af- ter treatment, the following items were measured： body mass index （BMI）, fasting plasma glucose （FPG）, 2-hour postprandial blood glucose （2hPG）, hemoglobin A1C （HbA1C）, fasting C-P, 2-hour postprandial C-P, glucagon （GC）, somatostatin （SS）, tri- glyeerides （TG）, and total cholesterol （TC）. Results After 12-week exenatide therapy, the BMI,2hPG, HbA1C, TG,TC, GC significantly declined （t =2.54 6.61,P〈0.05）; the SS and 2-hour postprandial C-P elevated （t =7.44,2.62;P〈0.05）; FPG ten- ded to decline, and fasting C-P tended to elevate, but the difference was not significant. Conclusion For obesity type 2 diabetes with uncontrollable blood glucose, exenatide can be used to effectively decrease the blood sugar, control body mass, improve lipid metabolism and reduce the risk of hypoglycemia.
出处
《青岛大学医学院学报》
CAS
2013年第2期157-159,共3页
Acta Academiae Medicinae Qingdao Universitatis
关键词
艾塞那肽
糖尿病
2型
肥胖症
治疗结果
exenatide
diabetes mellitus
type 2
obesity
treatment outcome
